Role of Neutrophils and CD4+ T Lymphocytes in the Primary and Memory Response to Nonimmunogenic Murine Mammary Adenocarcinoma Made Immunogenic by IL-2 Gene
Overview
Affiliations
TS/A is a spontaneous adenocarcinoma, apparently not immunogenic in BALB/cnAnCr mice. TS/A cells are unable to stimulate a syngeneic antitumor response either in vitro or in vivo. To evaluate the immunogenic potential of IL-2-releasing neoplastic cells, we used an expression vector to introduce the cDNA coding for murine IL-2 into TS/A cells. Six clones releasing between 30 and 6800 U of IL-2/10(5) cells/ml/48 h have been isolated. Both low (30 U, B1.30) and high (6000 U, B4.6000) IL-2-releasing clone are capable of stimulating a proliferative and cytotoxic response in syngeneic cultures. While the B1.30 clone grows in 60% of syngeneic mice with a delayed pattern, the five clones that release higher levels of IL-2 are promptly rejected. Rejection is associated with neutrophil infiltration, the intensity of which is directly proportional to the amount of IL-2 released. NK cells and CD4+ lymphocytes are uninfluential, whereas CD8+ lymphocytes play only a minor role. This neutrophil-dominated rejection leaves a long-lasting, tumor-specific, T lymphocyte-mediated immune memory. For its induction, CD4+ lymphocytes are required. Their specific activation appears to depend on both the amount of IL-2 released and the granulocyte-mediated reaction that may lead to a more efficient presentation of tumor-associated Ag. These data support the notion that, after transduction of IL-2 gene, cancer cells may elicit an immune antitumor response, and stress the potential use of IL-2 as a component of new tumor vaccines.
Leveling Up the Controversial Role of Neutrophils in Cancer: When the Complexity Becomes Entangled.
Sionov R Cells. 2021; 10(9).
PMID: 34572138 PMC: 8465406. DOI: 10.3390/cells10092486.
The Neutrophil: The Underdog That Packs a Punch in the Fight against Cancer.
Ustyanovska Avtenyuk N, Visser N, Bremer E, Wiersma V Int J Mol Sci. 2020; 21(21).
PMID: 33105656 PMC: 7659937. DOI: 10.3390/ijms21217820.
Mosallaei M, Simonian M, Ehtesham N, Karimzadeh M, Vatandoost N, Negahdari B Cancer Gene Ther. 2020; 27(12):854-868.
PMID: 32418986 DOI: 10.1038/s41417-020-0179-6.
Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model.
De Giovanni C, Nicoletti G, Landuzzi L, Palladini A, Lollini P, Nanni P Cancers (Basel). 2019; 11(12).
PMID: 31783695 PMC: 6966465. DOI: 10.3390/cancers11121889.
Sun B, Qin W, Song M, Liu L, Yu Y, Qi X Int J Biol Sci. 2018; 14(14):2103-2113.
PMID: 30585273 PMC: 6299367. DOI: 10.7150/ijbs.29297.